Related Experiment Video
Updated: May 15, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Contemporary treatment of systemic lupus erythematosus: an update for clinicians
Maame B Amissah-Arthur1, Caroline Gordon
1Professor Caroline Gordon, MA, MD, FRCP (UK) Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK, and School of Immunity and Infection, The University of Birmingham, Birmingham, UK.
Abstract:
The prognosis for patients with systemic lupus erythematosus (SLE) has improved significantly, with 20-year survival now approximately 80% owing partly to effective treatment. SLE treatment has evolved from the use of conventional drugs such as hydroxychloroquine and corticosteroids, nonspecific immunosuppressants including mycophenolate mofetil, to targeting selective components of the immune cascade with a view to increased efficacy, tolerability and safety profile. These novel treatments include B-cell-depleting antibodies and fusion proteins that block the costimulatory pathways of B and T cells. A discussion of these pharmacological options and ongoing research forms the basis of this review.
More Related Videos
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Nephrotic Syndrome III : Nursing Management
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome I : Introduction
Pericarditis III: Medical Management
